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ABSTRACT
Cat-scratch disease involves a prolonged and ⁄ or complicated course, and lymph node drainage is
usually required. Culture and molecular techiques often yield negative results, but immunoﬂuorescence
assays may give early information, and elevated antibodies may persist for months. Cat-scratch disease
should be suspected in patients with prominent swelling of lymph nodes draining from the upper limbs,
limited systemic involvement, and typical epidemiological–clinical features. The temporal antibody
response during the sub-acute course remains unknown. Although biomolecular assays are available,
the time between onset and investigation is an obstacle to positive results1 . The role of surgical
debridement and the unpredictable activity of antimicrobial agents warrant further investigation.
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The spectrum of disease caused by Bartonella
spp. has expanded rapidly over the past two
decades, prompted by the association of cat-
scratch disease (CSD), AIDS-related bacillary
angiomatosis and bacillary peliosis with the
fastidious Gram-negative bacillus identiﬁed ini-
tially as Rochalimaea henselae, but placed subse-
quently, on the basis of genomic sequence
analysis, in the genus Bartonella [1,2]. Five major
Bartonella spp. have been found to be pathogenic
(B. bacilliformis, B. henselae, B. quintana, B. eliz-
abethae and B. clarridgeiae), but other members of
the genus have been found in animal reservoirs
(rodents and moles) [1–4]. About 40% of domes-
tic cats may have asymptomatic B. henselae
infection accompanied by bacteraemia, which
may persist for > 1 year and represents the most
obvious risk for CSD.
The usual presentation of B. henselae infection is
CSD, a sub-acute, regional lymphadenitis usually
persisting for 3 weeks or more. This disease, ﬁrst
thought to be caused by Aﬁpia felis, has been
attributed to B. henselae since 1992, following
isolation of B. henselae from healthy cats and the
development of reliable diagnostic tests [1,3–5].
Another species, B. clarridgeiae, has been associ-
ated rarely with cases of CSD [1,2]. B. henselae
antibody is found in 84–100% of CSD patients,
and culture from lymph nodes and detection of
speciﬁc genomic sequences of B. henselae have
been achieved [3,4].
Epidemiologically, 87–99% of patients with
CSD report contact with cats (whose infection is
transmitted by the cat ﬂea Ctenocephalides felis).
The exact mechanism of cat-to-human transmis-
sion remains unclear, although a scratch or bite
is documented in c. 50% of episodes. Cases often
involve children or adolescents, but can occur at
any age [2,5]. In a study of 130 seropositive
patients, it was found that 79.2% of cases
occurred at an age of < 18 years [2,6,7]. Extensive
studies of B. henselae seroprevalence are lacking,
but infections rarely occur in the absence of
suggestive signs and symptoms [8].
The CSD incubation period is estimated to be
7–15 days. A few non-pruritic papules or papule-
vesicles (often overlooked) may follow the inocu-
lation lesion, and these precede the characteristic
regional lymph node involvement. The ﬁrst and
second set of lymph nodes draining the infection
site are usually affected (cervical, axillary or
epitrochlear), but more distant sites may be
involved infrequently [1–7]. The duration of
lymph node enlargement is usually limited to
1–2 months, but may be > 1 year [1–5], despite
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surgery and antimicrobial therapy. The ‘Parinaud
oculoglandular syndrome’ is characterised by a
conjunctival site of entry, followed by pre-auric-
ular lymphadenopathy [2,6,9].
Although CSD is usually self-limiting within a
few weeks or months, a locally severe disorder or
disseminated illness may occur. Granulomatous
disease of the liver, spleen, mesenteric lymph
nodes, heart and bone, with general or focal signs
and symptoms, has been reported [1–5,10,11].
Encephalopathy occurs 2–3 weeks after the onset
of disease as a complication in 5% of patients, with
sudden seizures, altered behaviour or conscious-
ness, peripheral facial nerve paresis and myelora-
diculitis, but self-resolution is the rule [1,3,5].
Haematological manifestations include haemolyt-
ic anaemia, thrombocytopenia and eosinophilia,
while rare cases of leukocytoclastic vasculitis,
mediastinal masses, atypical pneumonia and
pleural effusion, and other presentations mimick-
ing collagen vascular diseases, may occur [1–5,10].
The differential diagnosis of CSD includes virtu-
ally all possible causes of lymphadenopathy, e.g.,
pyogenic and Toxoplasma gondii lymphadenitis,
atypical mycobacterial infection, haematological
and solid-organ malignancies, tularaemia, and
brucellosis [1–5]. Of 454 patients with unclear
head–neck masses, 61 (13.4%) were conﬁrmed as
having CSD [11]. In another series, prolonged
fever of unknown origin was the predominant
symptom in 2.8% of 130 cases, while 30% of
patients with documented serological B. henselae
infection lacked any lymphadenopathy [6].
Immune effector cells producing angiogenic
cytokines following stimulation with B. henselae
may have a role in pathogenesis for immunocom-
promised hosts developing bacillary angiomatosis
and peliosis, while the typical slowly progressing
granulomatous response of healthy patients might
be triggered by an enhanced immune response to
bacterial antigens [3,4,12].
CSD may be suspected on epidemiological–
clinical grounds, but serological assays that show
a good correlation between infection and disease
are available, including indirect immunoﬂuores-
cence, haemagglutination and enzyme-linked
assays. However, comparative studies are lack-
ing, the timing of the IgG and IgM response
remains variable, and cross-reactivity between
different Bartonella spp. may occur [1–3,8,13,14].
In a long-term parallel serological–clinical fol-
low-up of 98 CSD patients by ELISA for a
median of 35.3 weeks [14], anti-B. henselae IgM
was detected in 53% of subjects for 3 months,
while 25% of patients remained IgG-seropositive
for > 12 months. Unfortunately, no association
was found between the kinetics of the antibody
response, the evolution of clinical symptoms
(typical or atypical), and the overall duration of
illness or time to complete cure [14]. Use of a
coupled immunoﬂuorescence test with both
serum and lymph node smears has improved
the sensitivity and speciﬁcity of CSD diagnosis
signiﬁcantly (up to 97.4% based on at least one
positive test), and this approach can be used
when molecular tests are unavailable [15].
Although serology is the cornerstone of the
aetiological diagnosis of CSD, different tech-
niques vary in sensitivity according to the anti-
gen, cut-off levels and other procedures used, so
that results from different series are not compar-
able [8,13,14]. Culture, PCR and other molecular
tests are usually conﬁned to reference centres
[3,11,13]. Recovery from blood requires prolonged
incubation in highly enriched media or endothel-
ial cell lines, while B. henselae DNA can be
detected only in the ﬁrst 6 weeks of the disease.
Consequently, molecular assays are often frustra-
ting, since most patients are only investigated
several weeks following the onset of disease, and
the incubation period is often overlooked. Other
routine tests are unhelpful, although hepatic
transaminases may be elevated, and ultrasono-
graphy and ⁄ or computed tomography exami-
nations may show enlarged lymph nodes and
disclose the infrequent granulomatous involve-
ment of visceral organs [1,2]. Diagnostic imaging
may also help in the differential diagnosis of
the most common localisation of lymphadeno-
pathy (the epitrochlear region), and it has been
reported that lymphadenopathy at this site is
caused predominantly by B. henselae infection
[16].
The need for, selection and duration of anti-
microbial therapy for CSD remain contentious.
Some authors claim that there is no beneﬁt,
compared to conservative symptomatic care and
follow-up, for immunocompetent, otherwise
healthy paediatric or adult patients, while others
attribute a signiﬁcant role to a broad spectrum of
antibiotics [1–5,17]. Most isolates of Bartonella spp.
appear to be susceptible in vitro to a wide range
of b-lactams, rifampicin, erythromycin and
tetracyclines, while sensitivity to clindamycin,
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quinolones and co-trimoxazole seems to be vari-
able [1–4,18]. However, a remarkable discordance
between the in-vitro and in-vivo activity of
several antibiotics has been demonstrated. Con-
trolled clinical data are scarce, but in most studies
a poor response to penicillin derivatives and other
compounds has been found, despite apparent
susceptibility in vitro [5,18]. A single placebo-
controlled trial with azithromycin showed some
initial beneﬁt, but contrasting long-term results
[17]. Therefore, the role and mode of antimicro-
bial therapy for CSD deserve investigation. If
treatment seems indicated clinically, novel macro-
lides, co-trimoxazole, rifampicin, ﬂuoroquinolo-
nes and gentamicin might be ﬁrst-choice agents
[2,17,18]. Corticosteroids as adjunctive therapy
have been suggested for long-lasting CSD [19] if
an exaggerated immune response is present
[4,5,13], but no controlled data are available.
Suppurative nodes that become tense and painful
should be drained, but incision of non-suppura-
tive lesions should be avoided, as chronic drain-
ing ﬁstulae or compromised healing may result
[1,2,5,7].
Transmission of CSD between humans has not
been documented. However, infrequent concom-
itant disease may occur in siblings [20]. Prevent-
ive measures involve avoidance of close contact
with cats and cat ﬂeas, and an improved aware-
ness of the risk from cat (especially kitten)
scratches.
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